Raymond James Financial Inc. purchased a new stake in shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA - Free Report) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund purchased 411,077 shares of the company's stock, valued at approximately $4,793,000. Raymond James Financial Inc. owned 0.40% of Intellia Therapeutics as of its most recent filing with the Securities & Exchange Commission.
A number of other hedge funds and other institutional investors have also bought and sold shares of the stock. State Street Corp boosted its position in shares of Intellia Therapeutics by 17.9% in the third quarter. State Street Corp now owns 5,143,534 shares of the company's stock worth $105,700,000 after purchasing an additional 780,754 shares during the period. ARK Investment Management LLC lifted its stake in shares of Intellia Therapeutics by 2.3% during the 4th quarter. ARK Investment Management LLC now owns 12,536,386 shares of the company's stock valued at $146,174,000 after buying an additional 280,946 shares in the last quarter. Two Sigma Advisers LP boosted its holdings in Intellia Therapeutics by 33.5% in the 3rd quarter. Two Sigma Advisers LP now owns 1,027,617 shares of the company's stock worth $21,118,000 after buying an additional 257,700 shares during the period. Sphera Funds Management LTD. grew its stake in Intellia Therapeutics by 108.8% during the third quarter. Sphera Funds Management LTD. now owns 291,080 shares of the company's stock valued at $5,982,000 after acquiring an additional 151,661 shares in the last quarter. Finally, Patient Square Capital LP bought a new stake in Intellia Therapeutics in the 3rd quarter valued at $2,642,000. Hedge funds and other institutional investors own 88.77% of the company's stock.
Insider Activity at Intellia Therapeutics
In other news, CEO John M. Leonard sold 26,807 shares of the firm's stock in a transaction that occurred on Friday, January 3rd. The shares were sold at an average price of $12.18, for a total transaction of $326,509.26. Following the transaction, the chief executive officer now directly owns 941,115 shares of the company's stock, valued at approximately $11,462,780.70. This trade represents a 2.77 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Insiders sold 29,000 shares of company stock worth $352,551 in the last 90 days. 3.20% of the stock is owned by corporate insiders.
Wall Street Analysts Forecast Growth
Several research analysts have commented on NTLA shares. The Goldman Sachs Group restated a "sell" rating and set a $9.00 price objective on shares of Intellia Therapeutics in a research report on Friday, February 28th. Barclays reduced their price objective on Intellia Therapeutics from $55.00 to $26.00 and set an "overweight" rating on the stock in a research note on Friday, February 28th. StockNews.com upgraded Intellia Therapeutics to a "sell" rating in a research report on Monday, March 3rd. Wells Fargo & Company reduced their price target on shares of Intellia Therapeutics from $60.00 to $50.00 and set an "overweight" rating on the stock in a research report on Friday, February 28th. Finally, HC Wainwright assumed coverage on shares of Intellia Therapeutics in a research report on Wednesday, March 5th. They set a "buy" rating and a $30.00 price objective for the company. Two equities research analysts have rated the stock with a sell rating, six have assigned a hold rating, eleven have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $37.56.
Check Out Our Latest Stock Analysis on Intellia Therapeutics
Intellia Therapeutics Stock Performance
Intellia Therapeutics stock traded down $0.33 during mid-day trading on Friday, hitting $8.07. The company's stock had a trading volume of 2,760,148 shares, compared to its average volume of 2,189,823. Intellia Therapeutics, Inc. has a one year low of $8.03 and a one year high of $28.18. The stock has a market cap of $835.38 million, a PE ratio of -1.48 and a beta of 1.97. The company has a 50 day moving average of $9.98 and a 200-day moving average of $13.77.
Intellia Therapeutics Profile
(
Free Report)
Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.
Further Reading
Before you consider Intellia Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Intellia Therapeutics wasn't on the list.
While Intellia Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
